分支狭窄病变市场－全球产业规模、份额、趋势、机会、预测：按应用、地区和竞争格局划分，2021-2031年

全球分叉病变市场预计将从 2025 年的 27.6 亿美元成长到 2031 年的 40.1 亿美元，复合年增长率为 6.42%。

冠状动脉分叉病变的特征是位于冠状动脉主要侧支起始部附近的复杂动脉狭窄，通常会涉及这些侧支。全球市场扩张的主要驱动力是复杂冠状动脉疾病盛行率的上升以及人口老化对先进心血管护理的需求。此外，介入性心臟病学领域的快速技术进步，例如药物释放型支架的改进和专用分叉器械的引入，透过改善手术效果并促进从传统搭桥手术向微创技术的转变，也推动了市场成长。

根据美国心臟协会引用的一项2024年核心实验室评估，45.2%的三支血管冠状动脉疾病患者至少存在一处真正的分叉病变。儘管患病率如此之高，但由于此类介入治疗的固有技术挑战，市场仍面临着巨大的障碍。复杂的解剖结构通常需要先进的支架留置技术，与标准手术相比，这可能导致较低的成功率和更高的长期不利事件风险，例如支架内血管再阻塞和血栓症。

市场驱动因素

冠状动脉疾病和复杂病变在全球范围内的日益普遍是推动全球分叉病变市场发展的主要因素。随着老年人族群心血管疾病发生率的上升，治疗性介入以解决复杂解剖闭塞的需求也日益增长。根据美国心臟协会 (AHA) 于 2024 年 1 月发布的《2024 年心血管和中风统计更新》显示，目前约有 1.269 亿美国人患有某种形式的心血管疾病，这一数字令人震惊。如此庞大的患者群体迫使医疗机构优先采用先进的导管介入技术，从而推动了商业活动的发展，美Medtronic力公司截至 2024 年 5 月的财年财务业绩（其心血管产品组合的年收入为 118.31 亿美元）便印证了这一点。

专用分叉支架系统的技术创新同样至关重要，它从根本上改变了治疗环境，提高了手术的安全性和有效性。该行业正迅速从临时支架置入转向整合先进的专用器械和高解析度成像技术，从而克服了进入侧支血管的技术难题。随着医院更新设备，这种发展正在推动市场渗透。例如，波士顿科学公司在2024年1月的财报中报告称，心血管业务销售额成长了13.9%，这主要归功于现代介入疗法的应用。这些财务指标表明，技术进步使临床医生更有信心地进行复杂的经皮冠状动脉介入治疗。

市场挑战

分叉病变治疗固有的技术复杂性对全球分叉病变市场构成重大障碍。这些病变中常见的解剖异常往往会阻碍支架的最佳扩张和黏附，给介入性心臟病专家带来挑战。这种复杂性导致手术成功率存在差异，限制了采用新型、更昂贵的分叉病变专用器械所需的广泛可靠性。当临床医生预期技术失败或长期併发症的风险较高时，他们就不太愿意对复杂病例采用经皮冠状动脉介入治疗，最终限制了整体的潜在市场需求。

根据美国心臟学会2024年发表的临床数据，接受标准血管造影术经皮冠状动脉介入治疗（PCI）治疗复杂分叉病变的患者，两年内发生重大心血管事件的机率高达14.1%。如此高的併发症发生率，包括目标病变血管重组和心肌梗塞，进一步加深了人们对此手术风险的认知。因此，持续存在的安全隐患阻碍了市场成长，人们倾向于选择保守治疗或外科手术，而不是积极地对高风险解剖结构应用导管介入策略。

市场趋势

血管内影像技术，特别是血管内超音波（IVUS）和光学同调断层扫描（OCT）的广泛应用，正在从根本上改变分支病变的治疗方式。临床医生日益认识到，仅靠血管造影术往往不足以评估主干和侧支血管复杂的解剖结构，因此辅助影像技术在优化支架尺寸和黏附性方面的应用激增。这种转变对于最大限度地减少支架失败和提高长期血管通畅性至关重要。为了反映这一需求，波士顿科学公司在其2025财年财报中公布，其心血管部门（包括先进的多重模式导航系统）的有机净销售额年增27.4%。

同时，秉持着「不留任何后遗症」的治疗理念，药物释放型球囊（DCB）在侧支血管治疗中的应用正在迅速扩展。此策略透过将抗增殖药物直接输送至血管壁来解决血管再阻塞，无需在侧支血管中留下永久性金属植入，保留了未来的治疗选择。随着越来越多的临床证据支持其在复杂解剖结构中的安全性和有效性，这种方法正日益受到关注。例如，2025年5月《心血管商业》（Cardiovascular Business）杂誌的报导报道，Prevail DCB在复杂冠状动脉疾病患者中实现了7.4%的2年靶病变血运重建率，凸显了其不断扩大的临床效用。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球分支与狭窄市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 透过应用（週边血管、冠状动脉）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美分支狭窄病变市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲分支狭窄市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区分支血管狭窄市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章 中东和非洲分支和狭窄病变市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲分支血管狭窄病变市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球分支狭窄市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Boston Scientific Corp.
• Abbott Laboratories Inc.
• Cardinal Health Inc.
• Medtronic Plc
• CR Bard, Inc
• Johnson & Johnson Services, Inc.
• Spectranetics Corp
• Terumo Medical Corp.
• Poseidon Medical Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Bifurcation Lesions Market is projected to expand from USD 2.76 billion in 2025 to USD 4.01 billion by 2031, reflecting a compound annual growth rate of 6.42%. Coronary bifurcation lesions are characterized as complex arterial stenosis located near, and often involving, the origin of a major side branch within the coronary vessels. This global market expansion is primarily fueled by the rising prevalence of complex coronary artery disease and an aging population necessitating advanced cardiovascular care. Additionally, rapid technological advancements in interventional cardiology, such as the improvement of drug-eluting stents and the launch of specialized bifurcation devices, are bolstering market growth by improving procedural outcomes and encouraging a shift from traditional bypass surgery to minimally invasive techniques.

According to a 2024 core laboratory assessment cited by the American Heart Association, 45.2% of patients with three-vessel coronary artery disease presented with at least one true bifurcation lesion. Despite this substantial prevalence, the market encounters a major obstacle due to the inherent technical difficulty of these interventions. The complex anatomy frequently requires demanding stenting techniques, which can lead to lower success rates and an increased risk of long-term adverse events, such as in-stent restenosis or thrombosis, when compared to standard procedures.

Market Driver

The escalating global prevalence of Coronary Artery Disease and complex lesions serves as the primary catalyst for the Global Bifurcation Lesions Market. As cardiovascular morbidity increases, particularly among the aging demographic, the need for interventions to address difficult anatomical blockages becomes more frequent. The burden is significant; the American Heart Association's "2024 Heart Disease and Stroke Statistics Update" from January 2024 notes that approximately 126.9 million Americans are currently living with some form of cardiovascular disease. This immense patient volume compels healthcare providers to prioritize advanced catheterization capabilities, driving commercial activity as evidenced by Medtronic's May 2024 financial results, which reported $11.831 billion in annual revenue for their Cardiovascular Portfolio.

Technological innovations in dedicated bifurcation stent systems are equally vital, fundamentally reshaping the treatment landscape by enhancing procedural safety and efficacy. The industry is moving rapidly from provisional stenting toward sophisticated, purpose-built devices and the integration of high-resolution imaging to overcome the technical difficulties of side-branch access. This evolution drives market uptake as hospitals modernize their inventories; for instance, Boston Scientific reported a 13.9% increase in Cardiovascular segment sales in their January 2024 financial results, attributed largely to the adoption of modern interventional therapies. These financial indicators demonstrate how technical progress empowers clinicians to perform complex percutaneous coronary interventions with greater confidence.

Market Challenge

The inherent technical complexity involved in treating bifurcation lesions acts as a significant barrier to the Global Bifurcation Lesions Market. The anatomical irregularities typical of these lesions often hinder optimal stent expansion and apposition, creating a difficult environment for interventional cardiologists. This complexity results in variable procedural success rates and limits the widespread confidence necessary to adopt newer, premium bifurcation-specific devices. When operators anticipate a high likelihood of technical failure or long-term complications, they are less inclined to utilize percutaneous coronary intervention for complex cases, thereby restricting the market's total addressable volume.

Clinical data highlighted by the American College of Cardiology in 2024 revealed that patients undergoing standard angiography-guided percutaneous coronary intervention for complex bifurcation lesions experienced a major adverse cardiac event rate of 14.1% over a two-year period. This high incidence of complications, including target lesion revascularization and myocardial infarction, reinforces the perception of risk associated with these procedures. Consequently, persistent safety concerns impede market growth by discouraging the aggressive application of catheter-based strategies in favor of conservative management or surgical alternatives for high-risk anatomies.

Market Trends

The widespread integration of intravascular imaging modalities, specifically Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT), is fundamentally transforming bifurcation lesion management. Clinicians increasingly recognize that angiography alone is often inadequate for assessing the complex anatomy of main and side branches, prompting a surge in the use of adjunctive imaging to optimize stent sizing and apposition. This shift is essential for minimizing stent failure and improving long-term vessel patency; reflecting this demand, Boston Scientific's February 2025 financial results reported that its Cardiovascular segment, including advanced multi-modality guidance systems, achieved an organic net sales growth of 27.4% compared to the prior year.

Simultaneously, the utilization of Drug-Coated Balloons (DCB) for side branch interventions is growing rapidly, supported by the "leave nothing behind" therapeutic philosophy. This strategy addresses in-stent restenosis by delivering anti-proliferative medication directly to the vessel wall without leaving a permanent metal implant in the side branch, thus preserving future treatment options. The approach is gaining traction as new clinical evidence confirms its safety and efficacy for complex anatomies. For example, an article in Cardiovascular Business from May 2025 noted that the Prevail DCB demonstrated a favorable two-year target lesion revascularization rate of 7.4% in patients with complex coronary artery disease, highlighting its expanded clinical utility.

Key Market Players

• Boston Scientific Corp.
• Abbott Laboratories Inc.
• Cardinal Health Inc.
• Medtronic Plc
• C. R. Bard, Inc
• Johnson & Johnson Services, Inc.
• Spectranetics Corp
• Terumo Medical Corp.
• Poseidon Medical Inc

Report Scope

In this report, the Global Bifurcation Lesions Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bifurcation Lesions Market, By Application

• Peripheral
• Coronary

Bifurcation Lesions Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bifurcation Lesions Market.

Available Customizations:

Global Bifurcation Lesions Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bifurcation Lesions Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Application (Peripheral, Coronary)
  • 5.2.2. By Region
  • 5.2.3. By Company (2025)
• 5.3. Market Map

6. North America Bifurcation Lesions Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Application
  • 6.2.2. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Bifurcation Lesions Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Application
  • 6.3.2. Canada Bifurcation Lesions Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Application
  • 6.3.3. Mexico Bifurcation Lesions Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Application

7. Europe Bifurcation Lesions Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Application
  • 7.2.2. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Bifurcation Lesions Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Application
  • 7.3.2. France Bifurcation Lesions Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Application
  • 7.3.3. United Kingdom Bifurcation Lesions Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Application
  • 7.3.4. Italy Bifurcation Lesions Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Application
  • 7.3.5. Spain Bifurcation Lesions Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Application

8. Asia Pacific Bifurcation Lesions Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Application
  • 8.2.2. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Bifurcation Lesions Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Application
  • 8.3.2. India Bifurcation Lesions Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Application
  • 8.3.3. Japan Bifurcation Lesions Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Application
  • 8.3.4. South Korea Bifurcation Lesions Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Application
  • 8.3.5. Australia Bifurcation Lesions Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Application

9. Middle East & Africa Bifurcation Lesions Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Application
  • 9.2.2. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Bifurcation Lesions Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Application
  • 9.3.2. UAE Bifurcation Lesions Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Application
  • 9.3.3. South Africa Bifurcation Lesions Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Application

10. South America Bifurcation Lesions Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Application
  • 10.2.2. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Bifurcation Lesions Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Application
  • 10.3.2. Colombia Bifurcation Lesions Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Application
  • 10.3.3. Argentina Bifurcation Lesions Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Bifurcation Lesions Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Boston Scientific Corp.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Abbott Laboratories Inc.
• 15.3. Cardinal Health Inc.
• 15.4. Medtronic Plc
• 15.5. C. R. Bard, Inc
• 15.6. Johnson & Johnson Services, Inc.
• 15.7. Spectranetics Corp
• 15.8. Terumo Medical Corp.
• 15.9. Poseidon Medical Inc

16. Strategic Recommendations

17. About Us & Disclaimer